Transmission of Bordetella pertussis to Young Infants

Wendelboe, Aaron M.; Njamkepo, Elisabeth; Bourillon, A.; Floret, D.; Gaudelus, J.; Gerber, Michael A.; Grimprel, E.; Greenberg, David; Halperin, Scott A.; Liese, Johannes G.; Munoz-Rivas, Flor; Teyssou, R.; Guiso, Nicole; Rie, Annelies Van

doi:10.1097/01.inf.0000258699.64164.6d

Cited by 418 publications

(271 citation statements)

References 32 publications

Supporting

Mentioning

232

Contrasting

Unclassified

Order By: Relevance

“…An increase in the number of new cases has been observed in vaccinated adolescents and adults, who may contaminate infants who are not yet fully immunized. [2][3][4][5] Since 1998, the administration of a pertussis booster at age 11-13 years has been recommended in France and other countries in Europe and North America. Subsequent recommendations established in 2004 have promulgated the use of a second booster in adults who are in contact with infants, these include health professionals in contact with children who are too young to have received three pertussis vaccinations (medical and paramedical staff in maternity, neonatal and pediatric departments managing infants, and medical and paramedical students), adults who are liable to become parents in the near future, and members of the household of a pregnant woman (children whose vaccinations are not up-to-date or adults who have not been vaccinated within the last 10 years).…”

Section: Introductionmentioning

confidence: 99%

Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: A placebo-controlled trial

Beytout

Launay²,

Guiso³

et al. 2009

Human Vaccines

Self Cite

View full text Add to dashboard Cite

IntroductionPertussis ("whooping cough") is potentially fatal in infants. 1 Over the last 50 years, infant vaccination programs have significantly reduced the clinical incidence of pertussis in industrialized countries. 1 However, protection against the infectious agent-the bacterium Bordetella pertussis-is only effective for about ten years. An increase in the number of new cases has been observed in vaccinated adolescents and adults, who may contaminate infants who are not yet fully immunized. [2][3][4][5] Since 1998, the administration of a pertussis booster at age 11-13 years has been recommended in France and other countries in Europe and North America. Subsequent recommendations established in 2004 have promulgated the use of a second booster in adults who are in contact with infants, these include health professionals in contact with children who are too young to have received three pertussis vaccinations (medical and paramedical staff in maternity, neonatal and pediatric departments managing infants, and medical and paramedical students), adults who are liable to become parents in the near future, and members of the household of a pregnant woman (children whose vaccinations are not up-to-date or adults who have not been vaccinated within the last 10 years). 2,[6][7][8] The administration of the pertussis booster in adults is complicated by the lack of any non-combined acellular pertussis vaccine. All available pertussis-booster vaccines for use in adults associate diphtheria, tetanus and/or poliovirus antigens. In France, there are currently two such vaccines: REPEVAX ® [manufactured by Sanofi Pasteur and licensed by Sanofi Pasteur MSD in the European Union (EU) and as ADACEL Polio ® outside the EU] and BOOSTRIX-TETRA ® (GlaxoSmithKline). 9,10 Both are combined adsorbed tetanus, diphtheria (adult formulation), acellular pertussis, inactivated poliovirus vaccines (Tdap-IPV). Inactivated poliovirus vaccine (IPV) has been used since the beginning of polio vaccination in France, and is included in all booster formulations (administered every 10 years in adults). Results: The safety of Tdap-IPV was similar when Tdap-IPV vaccine was administered one month after either Td-IPV or placebo: at seven days, 85.1% versus 93.4% subjects reported at least one reaction at the injection site, mainly pain (82.6% versus 92.1%); 40.5% versus 45.0%, at least one systemic AE (mainly headache: 26.4% versus 26.0%); fever concerned 1.7% of both groups. No serious vaccine-related AEs were reported. Both safety profiles corresponded to documented product characteristics.Conclusions: Tdap-IPV may be administered to adults one month after Td-IPV without exacerbating post-vaccination sideeffects.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: A placebo-controlled trial

Beytout

Launay²,

Guiso³

et al. 2009

Human Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is potentially effective for protecting newborn infants, as parents are often the primary reservoir and source of neonatal and infant infections. [4][5][6] Immunizing parents and siblings, carriers and grandparents as part of a cocooning strategy provides additional protection for the newborn. [7][8][9][10] Influenza and pertussis create a significant burden of disease affecting both mothers and newborns.…”

Section: Introductionmentioning

confidence: 99%

Increased awareness and health care provider endorsement is required to encourage pregnant women to be vaccinated

Collins

Alona

Tooher

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Maternal immunization is an important strategy recommended to protect both mothers and infants from serious infectious diseases; however uptake of maternal immunization is poor in Australia. This study aimed to gain an in-depth understanding of the decision making process and factors influencing a pregnant woman's decisions about recommended immunizations. This qualitative study used semi-structured interviews with open-ended questions to interview pregnant women. Data were analyzed using thematic analysis techniques and drew on the Health Belief Model. Pregnant women (n D 17) were asked about their attitudes toward immunization during pregnancy and their perceptions about risk during pregnancy. Women were also asked to detail their decision making process and factors influencing their decisions about immunizations in relation to pregnancy. Most of the participants were not aware of the immunizations recommended during pregnancy, in pregnancy planning or after delivery. In addition to endorsement by their health care provider (HCP), perception of risk and benefit, including risk of infection, previous vaccination experiences and assessing cost benefit play a vital role in women's decisions whether to be immunized while pregnant. Although the role of the healthcare provider in advising pregnant women about immunizations was identified as vitally important, the majority of women had not been advised of recommended vaccines by their healthcare provider. Healthcare providers are key to ensuring pregnant mothers are informed about recommended vaccines and these need to be more proactively supported and encouraged by healthcare providers. This is likely to have a positive effect on acceptance and uptake of immunization by pregnant women.

show abstract

“…Apibendrinat galima teigti, kad jauniausia tyrimo dalyvė paskutinį kartą nuo kokliušo buvo skiepyta maždaug prieš 16 metų, o vyresnės -ir dar seniau. Gauti tyrimo rezultatai ati-žmonės, esantys artimiausioje kūdikių aplinkoje, t. y. jų tėvai, broliai, seserys, seneliai [19][20][21][22]. Kokono strategijos pagrindinis tikslas -nuo kokliušo paskiepyti visus šeimos narius ir asmenis, artimai bendraujančius su kūdikiais (t. y. kūdikius prižiū-rinčius asmenis, medicinos įstaigų darbuotojus) ir taip sukurti sąlyginai saugią aplinką, kurioje tikimybė susidurti su kokliušu kūdikiui būtų labai maža.…”

Section: Rezultatų Aptarimasunclassified

Specifinių antikūnų prieš B. pertussis titrai gimdyvių ir virkštelių kraujyje

Ivaškevičius¹,

Ivaškevičienė²,

Usonis³

2015

AML

View full text Add to dashboard Cite

Įvadas. Lietuvoje, kaip ir daugelyje pasaulio šalių, sergamumas kokliušu plečiasi, nors skiepijimų apimtys nuo šios infekcijos ir yra didelės. Kokliušu serga įvairaus amžiaus asmenys, tačiau jis pavojingiausias naujagimiams ir pirmųjų gyvenimo mėnesių kūdikiams. Šiai vaikų amžiaus grupei apsaugą nuo kokliušo galėtų užtikrinti transplacentaliai gauti specifiniai antikūnai iš mamos organizmo. Tyrimo tikslas -nustatyti specifinių antikūnų prieš B. pertussis toksiną (anti-PT IgG) titrus gimdyvių ir kūdikių virkštelių kraujyje bei įvertinti tikėtiną naujagimių imlumą B. pertussis infekcijai.Tiriamieji ir tyrimo metodika. Siekiant įvertinti mamos ir naujagimio imunitetą kokliušui, buvo tiriamas gimdyvės ir virkštelės kraujas, jame nustatomi G klasės antikūnai prieš B. pertussis toksiną.Rezultatai. Iš viso išanalizuota 400 kraujo mėginių (200 gimdyvių ir 200 virkštelių), juose nustatytas anti-PT IgG kiekis. Beveik 87 % nėščių-jų buvo seronegatyvios, anti-PT IgG kiekis jų kraujyje siekė <20 EU/ml. Virkštelės kraujo mėginiuose anti-PT IgG <20 EU/ml buvo 72,5 %.Išvados. Mūsų tyrimo rezultatai atskleidė, kad tiek vaisingo amžiaus moterų, tiek virkštelės kraujyje kokliušui specifinių antikūnų kiekiai yra labai maži, jie neužtikrina naujagimių apsaugos nuo šios ligos. Dėl nepakankamo iš mamos organizmo gautų kokliušui specifinių antikūnų kiekio naujagimių imlumas B. pertussis infekcijai yra didelis.Raktažodžiai: kokliušas, gimdyvė, virkštelės kraujas, naujagimis

show abstract

Transmission of Bordetella pertussis to Young Infants

Cited by 418 publications

References 32 publications

Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: A placebo-controlled trial

Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: A placebo-controlled trial

Increased awareness and health care provider endorsement is required to encourage pregnant women to be vaccinated

Specifinių antikūnų prieš B. pertussis titrai gimdyvių ir virkštelių kraujyje

Contact Info

Product

Resources

About